Radotinib Induces Apoptosis of CD11b(+) Cells Differentiated from Acute Myeloid Leukemia Cells

Radotinib, developed as a BCR/ABL tyrosine kinase inhibitor (TKI), is approved for the second-line treatment of chronic myeloid leukemia (CML) in South Korea. However, therapeutic effects of radotinib in acute myeloid leukemia (AML) are unknown. In the present study, we demonstrate that radotinib si...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Sook-Kyoung, Noh, Eui-Kyu, Yoon, Dong-Joon, Jo, Jae-Cheol, Choi, Yunsuk, Koh, SuJin, Baek, Jin Ho, Park, Jae-Hoo, Min, Young Joo, Kim, Hawk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466365/
https://www.ncbi.nlm.nih.gov/pubmed/26065685
http://dx.doi.org/10.1371/journal.pone.0129853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466365/
https://www.ncbi.nlm.nih.gov/pubmed/26065685
http://dx.doi.org/10.1371/journal.pone.0129853

Ejemplares similares